Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 3/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25443840 | 0.89 | GNAO1 (0.37) | GNAO1GNAI3GNAI1CHRM3 | |
| SCHEMBL25443842 | 0.89 | GNAO1 (0.37) | GNAO1GNAI3GNAI1CHRM3 | |
| SCHEMBL26494065 | 0.86 | HRH3 (0.39) | GNAO1HRH3 | |
| SCHEMBL24712472 | 0.85 | CYP1A2 (0.42) | ACHECHRM5CHRM3 | |
| SCHEMBL23594475 | 0.84 | GNAO1 (0.36) | GNAO1GNAI3GNAI1HRH3 | |
| SCHEMBL21946386 | 0.83 | NCF1 (0.42) | GNAO1GNAI3GNAI1NCF1ACHE | |
| SCHEMBL25079106 | 0.83 | GNAO1 (0.35) | GNAO1HRH3 | |
| SCHEMBL26295651 | 0.82 | CHRM3 (0.40) | GNAO1GNAI3GNAI1HRH3CHRM2 | |
| SCHEMBL25075241 | 0.80 | PIK3CD (0.40) | GNAO1GNAI3GNAI1CHRM3 | |
| SCHEMBL26445312 | 0.80 | GNAO1 (0.37) | GNAO1HRH3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023004163-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |